Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis - PubMed (original) (raw)
Review
. 2009 Sep;15(9):1005-13.
doi: 10.1016/j.bbmt.2009.04.003. Epub 2009 Jun 10.
Affiliations
- PMID: 19660713
- DOI: 10.1016/j.bbmt.2009.04.003
Free article
Review
Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis
Mohamed A Kharfan-Dabaja et al. Biol Blood Marrow Transplant. 2009 Sep.
Free article
Abstract
Increased insight into the role of B lymphocytes in the pathophysiology of graft-versus-host disease has led to a number of studies assessing the efficacy of the anti-CD20 monoclonal antibody (mAb) rituximab in treating steroid-refractory chronic graft-versus-host disease (cGVHD). Findings vary greatly among these studies, however. We conducted a systematic review to summarize the totality of evidence on the efficacy of rituximab in steroid-refractory cGVHD. We performed a PubMed search and contacted experts in the field to identify relevant studies. Endpoints included overall response rate (including organ-specific) and ability of rituximab to allow dosage reduction of immunosuppressive therapies. Data were pooled under a random-effects model. Seven studies (3 prospective and 4 retrospective, with a total of 111 patients) met the inclusion criteria. The pooled proportion of overall response was 0.66 (95% confidence interval=0.57 to 0.74). There was no heterogeneity among the pooled studies. Response rates were 13% to 100% for cGVHD of the skin, 0 to 83% for cGVHD of the oral mucosa, 0 to 66% for cGVHD of the liver, and 0 to 38% for cGVHD of the lung. Common adverse events were related to infusion reactions or infectious complications. The relatively small number of patients and the varying criteria for reporting organ response and dosage reduction of steroids, among other limitations, hinders our ability to reach definitive conclusions on the overall efficacy of rituximab for cGVHD involving other organs.
Similar articles
- Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS, Engemann AM, Hammond JM. Bates JS, et al. Ann Pharmacother. 2009 Feb;43(2):316-21. doi: 10.1345/aph.1L386. Epub 2009 Feb 3. Ann Pharmacother. 2009. PMID: 19193571 Review. - Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U. von Bonin M, et al. Transplantation. 2008 Sep 27;86(6):875-9. doi: 10.1097/TP.0b013e318183f662. Transplantation. 2008. PMID: 18813113 - Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?
Deneberg S, Lerner R, Ljungman P, Ringden O, Hägglund H. Deneberg S, et al. Med Oncol. 2007;24(3):354-6. doi: 10.1007/s12032-007-0002-3. Med Oncol. 2007. PMID: 17873314 - Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH. Kim SJ, et al. Haematologica. 2010 Nov;95(11):1935-42. doi: 10.3324/haematol.2010.026104. Epub 2010 Jul 27. Haematologica. 2010. PMID: 20663943 Free PMC article. Clinical Trial. - Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Nakasone H, Sahaf B, Miklos DB. Nakasone H, et al. Int J Hematol. 2015 May;101(5):438-51. doi: 10.1007/s12185-015-1782-4. Epub 2015 Mar 27. Int J Hematol. 2015. PMID: 25812839 Review.
Cited by
- Recent advances in graft-versus-host disease.
Flinn AM, Gennery AR. Flinn AM, et al. Fac Rev. 2023 Mar 6;12:4. doi: 10.12703/r/12-4. eCollection 2023. Fac Rev. 2023. PMID: 36923700 Free PMC article. Review. - Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW. Baumrin E, et al. J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23. J Am Acad Dermatol. 2024. PMID: 36572064 Free PMC article. Review. - Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S, Huo WX, Yang Y, Shen MZ, Mo XD. Fan S, et al. Front Immunol. 2022 Aug 4;13:954268. doi: 10.3389/fimmu.2022.954268. eCollection 2022. Front Immunol. 2022. PMID: 35990629 Free PMC article. - Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY, Zhao P, Zhang Y, Wang JS. Zhang MY, et al. PLoS One. 2022 Jul 29;17(7):e0271979. doi: 10.1371/journal.pone.0271979. eCollection 2022. PLoS One. 2022. PMID: 35905125 Free PMC article. - Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
Baek DW, Cho HJ, Kim JH, Ahn JS, Kim HJ, Lim SN, Cheong JW, Kim SY, Lee HS, Won JH, Yhim HY, Sohn SK, Moon JH. Baek DW, et al. Cell Transplant. 2022 Jan-Dec;31:9636897221113789. doi: 10.1177/09636897221113789. Cell Transplant. 2022. PMID: 35861214 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous